TrialSignal
Clinical trial intelligence report
Neoadjuvant Chemotherapy With or Without Metformin in Early Breast Cancer.
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04387630
Status
UNKNOWN
Phase
PHASE2
Sponsor
Mansoura University
Executive brief
Investment-Ready Snapshot
Metformin is a widely used anti-diabetic drug. Several studies have pointed out a potentially beneficial effect of metformin therapy in diabetic cancer patients. Several studies are investigating the anti-tumor effect of metformin in early breast cancer. However, the enhancing effect of metformin on anti-tumor immunity has only been demonstrated in animal models. This study examines the immune effect of metformin in breast cancer patients treated with preoperative chemotherapy.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04387630
Indication
Breast Cancer
Modality
small molecule
Target
Metformin, Placebo oral tablet
Intervention
Metformin, Placebo oral tablet
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.